Speech-Language Pathologists in Belle Chasse, LA Accepting Medicare

8 Speech-Language Pathologists found. Showing 1 - 8

Mrs. Shilo Gagliano Shoemake Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 110 Hunt St, Belle Chasse, LA 70037 Phone: 504-858-3085

Shelby Serio, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13476 La-23, Belle Chasse, LA 70037 Phone: 504-595-6640

Ms. Laurene' Andree' Bossier, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 162 South Concord Road, Apt. A, Belle Chasse, LA 70037 Phone: 504-912-0117

Nataly Mayeaux Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13476 La-23, Belle Chasse, LA 70037 Phone: 504-595-6640

Leslie T Chauvin Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11 Parc Riverwood Dr, Belle Chasse, LA 70037 Phone: 504-812-5187

Ms. Suzette B Perrin, M.ED, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 514 Moncla Ave, Belle Chasse, LA 70037 Phone: 504-432-3825

Mrs. Catherine Dove Colvin Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 601 F Edward Hebert Blvd, Belle Chasse, LA 70037 Phone: 504-595-6120

Katherine Coll Mabou Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 539 F Edward Hebert Blvd, Belle Chasse, LA 70037 Phone: 504-595-6620

News Archive

Mayo Clinic to establish pencil beam proton scanning facilities in Minnesota, Arizona and Florida

Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

ICON agrees to acquire BeijingWits

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting Ltd., a leading CRO in China.

Roundup: States 'scrambling' on Medicaid budget; health costs for inmates, Ex-Cons; kids' insurance

Strapped states are scrambling to address Medicaid's ballooning costs before the federal government cuts back a critical source of funding this week. Medicaid is one of state's costliest burdens. And the weak economy swelled the rolls to record numbers. Nearly 49 million people - or almost one in six Americans - were covered by the safety net at the end of 2009, the latest figures available.

Pharmacist-included medical care teams help patients better control blood pressure

If you have hypertension, it pays to include a pharmacist in a medical care team. That's the upshot from research by the University of Iowa that found patients with uncontrolled hypertension had better blood pressure control when being cared for by pharmacists working in care teams (with a physician, for example) than patients who relied mostly on a doctor for medication guidance.

Read more Medical News

› Verified 5 days ago